Home > Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

NHL: Non-Hodgkin Lymphoma


Non-Hodgkin Lymphoma (NHL) usually starts with abnormal proliferation of B lymphocytes, T lymphocytes, or natural killer cells in lymphoid tissues. NHLs can arise from lymphocytes at various developmental stages and the disease characteristics depend on the cell of origin. Hence, NHLs represent a highly heterogeneous group of lymphoid malignancies, with variable frequency, epidemiology, biology, genetic abnormalities, clinical course, and outcomes.

NHL can be divided into two prognostic groups. Indolent subtypes grow and spread slowly, with patients displaying few signs and symptoms. Indolent NHLs have a relatively good prognosis with a median survival up to 20 years, but they usually are incurable in advanced clinical stage. Aggressive subtypes grow and spread rapidly. Patients may have severe symptoms, but a substantial number can be cured with intensive combination chemotherapy regimens. NHL is the most frequent hematologic malignancy in Europe, causing significant morbidity and mortality in both adults and children.

Key questions

By gathering data from multiple clinical trials, we can obtain a sufficient sample size to link molecular characteristics to clinical outcomes, thus providing insight in the molecular signatures of this heterogeneous group of malignancies and potentially revealing novel drug targets. In the future, this should lead to more efficient (personalized) treatments. Examples of key questions that HARMONY will address for NHL are:

Which molecular characteristics can predict disease course and drug response? For instance, T cell lymphoma usually is highly aggressive, but it displays significant clinical and molecular heterogeneity.

Which biomarkers can be used to assess drug response?

What are the most important unmet needs in patient care for specific subtypes of NHL?

NHL Features

HARMONY Leadership: NHL